Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
FLOVENT HFA is a metered-dose aerosol inhaler containing fluticasone propionate, a corticosteroid approved in 2004 by GSK. It is indicated for symptoms of hay fever and other upper respiratory allergies, working through immune function modulation and inflammation reduction via corticosteroid mechanisms. The product represents a mature, inhaled corticosteroid therapy positioned as a foundational treatment in allergic rhinitis and respiratory allergy management.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers
Worked on FLOVENT HFA at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moPatent cliff in less than a year — expect lifecycle management and generic defense hiring
$395M Medicare spend — this is a commercially significant brand
The approaching loss of exclusivity (August 2026) creates immediate demand for product managers focused on brand defense strategies, managed care specialists negotiating formulary retention, and field teams managing transition to generic competition. Currently, zero open roles are linked to this product, suggesting mature team stability. Relevant skill sets include managed care economics, generic transition planning, and payer relationship management.